Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy

Semin Cancer Biol. 2022 Nov;86(Pt 3):732-742. doi: 10.1016/j.semcancer.2021.07.005. Epub 2021 Jul 15.

Abstract

The lung microbiome plays an essential role in maintaining healthy lung function, including host immune homeostasis. Lung microbial dysbiosis or disruption of the gut-lung axis can contribute to lung carcinogenesis by causing DNA damage, inducing genomic instability, or altering the host's susceptibility to carcinogenic insults. Thus far, most studies have reported the association of microbial composition in lung cancer. Mechanistic studies describing host-microbe interactions in promoting lung carcinogenesis are limited. Considering cancer as a multifaceted disease where epigenetic dysregulation plays a critical role, epigenetic modifying potentials of microbial metabolites and toxins and their roles in lung tumorigenesis are not well studied. The current review explains microbial dysbiosis and epigenetic aberrations in lung cancer and potential therapeutic opportunities.

Keywords: Cancer treatments; Epigenetic dysregulations; Lung cancer; Lung microbiome; Microbial dysbiosis.

Publication types

  • Review

MeSH terms

  • Cell Transformation, Neoplastic
  • Dysbiosis / complications
  • Dysbiosis / genetics
  • Epigenesis, Genetic
  • Humans
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / therapy
  • Microbiota*